Treatment of patients w/ thrombocythemia, secondary to myeloproliferative neoplasms, to reduce elevated platelet count & risk of thrombosis & to ameliorate associated symptoms including thrombo-hemorrhagic events.
Adult Initially 0.5 mg qds or 1 mg bd. Ped patient Initially 0.5 mg daily. Dose may be titrated after 1 wk. Max dose increment: 0.5 mg daily in any 1 wk. Max dose: 10 mg daily or 2.5 mg as single dose. Patient w/ moderate hepatic impairment (Child Pugh score 7-9) Initially 0.5 mg daily, may be increased if therapy has been tolerated for 1 wk. Max dose increment: 0.5 mg daily in any 1 wk.
View Agrylin overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Special Precautions
Reports of torsades de pointes & ventricular tachycardia; pulmonary HTN; ILDs (including allergic alveolitis, eosinophilic pneumonia, & interstitial pneumonitis). Do not use in patients w/ known risk factors for QT interval prolongation. May cause vasodilation, tachycardia, palpitations, & CHF. Therapy requires clinical monitoring, including CBCs, assessment of hepatic & renal function, & electrolytes. Evaluate patients for signs & symptoms of underlying cardiopulmonary disease prior to initiating & during therapy. Concomitant use w/ aspirin & other drugs known to cause bleeding (eg, anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, SSRIs). Increased anagrelide exposure & increased risk of QTc prolongation in patients w/ hepatic impairment. Avoid use in patients w/ severe hepatic impairment. Pregnancy. May impair female fertility. Breastfeeding is not recommended during treatment & for 1 wk following the last dose. No data for ped patients <7 yr.
Sign Out
